Daiichi Sankyo Concludes pCPA Letter of Intent for Vanflyta(TM) in Newly Diagnosed FLT3-ITD Positive AML

The three press releases cover distinct but routine moves in Daiichi Sankyo’s oncology pipeline and business development. Chronologically: - On 1 April 2026, Nuvation Bio amended its license to acquire Japan rights to safusidenib from Daiichi Sankyo, gaining worldwide development and commercialization rights. Daiichi Sankyo, the licensor, transfers its remaining territorial rights to a partner that already had ex‑Japan rights. The move allows expansion of the pivotal Phase 3 SIGMA study into Japan, but Daiichi Sankyo’s downstream participation is now limited to potential milestone or royalty payments (not disclosed). - On 16 April 2026, Interna Therapeutics announced a preclinical research collaboration with Daiichi Sankyo to evaluate its Molecular Nano Motor delivery platform. No financial terms were disclosed. This is an early‑stage technology exploration, not a product‑based partnership. - On 28 May 2026, Daiichi Sankyo concluded a Letter of Intent with the pan‑Canadian Pharmaceutical Alliance (pCPA) for Vanflyta® (quizartinib) in newly diagnosed FLT3‑ITD positive acute myeloid leukemia. Public reimbursement begins in Quebec in May 2026, covering induction, consolidation and maintenance phases. The approval was based on the QuANTUM‑First trial (HR=0.78, median OS 31.9 vs 15.1 months).

The most recent news – the pCPA letter of intent for Vanflyta – is a routine market‑access milestone. Vanflyta already received Health Canada Notice of Compliance in June 2025, so public reimbursement negotiations were a foreseeable next step. The agreement’s terms are not disclosed, and the impact is confined to one market (Canada). While positive, it does not constitute a new approval or a paradigm‑shifting data readout. The efficacy numbers quoted reinforce the drug’s profile but were previously published in The Lancet. No unexpected upside is signaled.
The earlier two releases are also routine: out‑licensing remaining rights to a partner and initiating a preclinical discovery collaboration are standard industry moves. None of these collectively alter the company’s risk/reward profile materially. The rating therefore is Routine – Positive.

Daiichi Sankyo is a global pharmaceutical company with a focus on oncology and cardiovascular care. Based on the provided releases, its lead asset highlighted is Vanflyta® (quizartinib), an oral FLT3 inhibitor for FLT3‑ITD positive AML. The company is also active in targeted delivery technologies (Interna collaboration) and previously held Japanese rights to the IDH1‑mutant glioma candidate safusidenib, which it has since out‑licensed to Nuvation Bio. The company’s research collaborations indicate an interest in next‑generation delivery platforms.